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A Ab bs st tr ra ac ct t
Lynch syndrome (HNPCC) is a dominantly inherited disorder characterized by germline defects in DNA mismatch
repair (MMR) genes and the development of a variety of cancers, predominantly colorectal and endometrial. We
present a 44-year-old woman who was shown to carry the truncating MSH2 gene mutation that had previously
been identified in her family. Recently, she had been diagnosed with an undifferentiated carcinoma of the thyroid
and an adenoma of her coecum. Although the thyroid carcinoma was not MSI-high (1 out of 5 microsatellites
instable), it did show complete loss of immunohistochemical expression for the MSH2 protein, suggesting that
this tumour was not coincidental. Although the risks for some tumour types, including breast cancer, soft tissue
sarcoma and prostate cancer, are not significantly increased in Lynch syndrome, MMR deficiency in the presence
of a corresponding germline defect has been demonstrated in incidental cases of a growing range of tumour
types, which is reviewed in this paper. Interestingly, the MSH2-associated tumour spectrum appears to be wider
than that of MLH1 and generally the risk for most extra-colonic cancers appears to be higher for MSH2 than for
MLH1 mutation carriers. Together with a previously reported case, our findings show that anaplastic thyroid
carcinoma can develop in the setting of Lynch syndrome. Uncommon Lynch syndrome-associated tumour types
might be useful in the genetic analysis of a Lynch syndrome suspected family if samples from typical Lynch syndrome
tumours are unavailable.
I In nt tr ro od du uc ct ti io on n
Lynch syndrome, also known as hereditary
nonpolyposis colorectal cancer (HNPCC), is an
autosomal dominant disorder associated with a germline
mutation in one of the DNA mismatch repair (MMR)
genes, most commonly MLH1 and MSH2 and less
frequently  MSH6 and  PMS2. Lynch syndrome is
characterized by a strongly increased risk of developing
colorectal cancer and several extra-colonic malignancies
including carcinomas of the endometrium, ovary, ureter,
stomach and small intestine. Tumours develop at 
a relatively young age. Although the risks for some
common types of cancer, for example breast cancer 
[1-3], or rarer tumour types, for example malignant
fibrous histiocytoma (MFH) [4], do not appear to be
significantly increased in Lynch syndrome, MMR
deficiency in the presence of a corresponding germline
defect has been demonstrated in incidental cases of
these tumours.H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2008; 6(1) 16
Rein P. Stulp, Johanna C. Herkert, Arend Karrenbeld, Bart Mol, Yvonne J. Vos, Rolf H. Sijmons
Here we report a 44-year-old woman from a Lynch
syndrome, Amsterdam positive family who was referred
for DNA testing. She had a recent history of a colorectal
adenoma and an undifferentiated carcinoma of her
thyroid and was shown to carry the truncating MSH2
mutation that was known to segregate in her family.
Traditionally, thyroid cancer is not considered to be part
of the Lynch syndrome tumour spectrum. Our findings,
however, suggest that this tumour was not coincidental,
but likely developed in association with the underlying
germline defect in the MSH2 gene. We reviewed the
literature on unusual manifestations of inherited
mismatch repair gene mutations.
M Me et th ho od ds s
After genetic counselling, DNA analysis of the
MSH2 gene was performed in this 44-year-old woman
by extracting DNA from lymphocytes, followed by 
a PCR amplification of exon 11 of the MSH2 gene. The
PCR product was analyzed by denaturing gradient gel
electrophoresis (DGGE) and compared with DNA from
a family member carrying the mutation [5].
Immunohistochemical staining for MLH1, PMS2,
MSH2 and MSH6 protein expression was performed
on formalin-fixed, paraffin-embedded sections of
tumour as described previously [6].
DNA was extracted from both tumour and normal
tissue. Microsatellite instability analysis was performed
on formalin-fixed, paraffin-embedded sections of
tumour and corresponding normal tissue. Following
DNA amplification using fluorescent labelled primers,
a panel of five microsatellites recommended by the
NCI [7] and consisting of BAT25, BAT26, D2S123,
D5S346 and D17S250 was analyzed for allelic shift.
The amplified PCR products were analyzed on an ABI
Genetic Analyzer.
We searched the English literature through Entrez
PubMed (www.ncbi.nlm.nih.gov/sites/entrez) using sets
of keywords to identify publications on tumours
reported in patients with germline mismatch repair gene
mutations. The reference lists of publications found
through this approach were searched for additional
relevant papers.
R Re es su ul lt ts s
Genetic analysis of the MSH2 gene in the patient
revealed the c.1704_1705delAG mutation, already
known to segregate in her family. Her undifferentiated
thyroid carcinoma showed complete loss of immunohi-
stochemical expression of the MSH2 and MSH6 protein
in the presence of normal positive internal controls, and
no loss of the MLH1 and PMS2 protein. Of the five
microsatellite markers tested, BAT26 showed instability.
Therefore the thyroid tumour was classified as MSI-low.
The acknowledged Lynch syndrome tumour
spectrum is shown in Table 1. The cumulative risks and
T Ta ab bl le e   1 1. .   Lynch syndrome tumour spectrum. Cumulative risks and average ages at diagnosis
T Tu um mo ou ur r   s si it te e M ML LH H1 1 M MS SH H2 2 M MS SH H6 6
m ma al le e f fe em ma al le e m ma al le e f fe em ma al le e m ma al le e f fe em ma al le e
Colorectum 22-65% 18-54% 30-73% 25-54% 60-70% 30-40%
(41-47 years) (41-47 years) (44-46 years) (44-46 years) (50-54  years) (50-54  years)
Endometrium 25-65% 22-61% 60-70%
(59 year) (59 year) (54 year)
Small intestine 7% 4% n.a.
Stomach 2% 4% n.a.
Ovary 3% 10% 10-28%
Ureter and renal pyelum 1% 12% n.a.
Brain n.a. 1% n.a.
Sebaceous glands n.a. n.a. n.a.
Pancreas 
Biliary tract
n.a. – not available
Shown in brackets are the ranges of average ages at diagnosis. For the PMS2 gene no cumulative risks are available.
Modified from a table developed by D Voskuil and RH Sijmons for the Dutch National Guidelines on Hereditary Colorectal Cancer (Menko F, ed. Richtlijn Erfelijke
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average ages of diagnosis shown in this table were
retrieved from papers reporting these data in proven
mutation carriers [8-17], rather than from papers that
had included untested patients and/or first-degree
relatives in their analyses. The reports on ‘unusual’
tumours in Lynch syndrome patients are presented in
Table 2. For comparison, we list the tumour spectrum
associated with bi-allelic MMR gene germline mutations
in Table 3.
D Di is sc cu us ss si io on n
Undifferentiated thyroid carcinoma is not commonly
associated with Lynch syndrome. In our patient the
immunohistochemical loss of expression for the MSH2
and MSH6 protein suggested that this tumour was not
coincidental, but due to the underlying mutation in the
MSH2 gene. Loss of MSH6 expression in tumours is
often observed in case of germline MSH2 mutations
and can be explained by loss of its stabilizing partner
MSH2. Broaddus et al. [18] contended that for both an
adrenal and a thyroid carcinoma an MSH2 gene
mutation was causally linked because the tumour
showed loss of MSH2 protein with immunohistochemical
staining, but retained expression of MLH1. This staining
pattern was similar to that seen in the more common
Lynch syndrome related malignancies in these families.
Although both adrenal and thyroid carcinoma showed
loss of MSH2 immunohistochemical expression, neither
tumour was microsatellite instable (MSI-high). Loss of
protein expression in the absence of MSI has been
observed before in Lynch syndrome, most notably in
patients with MSH6 mutations [6, 19].
In the past, the Lynch syndrome tumour spectrum
has primarily been defined through an epidemiological
and statistical approach. From a clinical point of view
this approach is of course still very valid as many
clinicians will be primarily interested in tumours that
T Ta ab bl le e   2 2. . Unusual tumours in patients with Lynch syndrome
T Tu um mo ou ur r   t ty yp pe e A Ag ge e    G Ge en ne e M Mu ut ta at ti io on n M MS SI I I IH HC C    I IH HC C    I IH HC C    R Re ef f. .
M ML LH H1 1 M MS SH H2 2 M MS SH H6 6
Non-Hodgkin’s lymphoma 48 MSH2 large rearrangement high + – – 45
Rhabdomyosarcoma, pleomorphic 34 MSH2 not published high + – ND 46
Breast carcinoma, ductal 49 MSH2 c.1705-1706 del GA high + – – 3
Fibrous histiocytoma, malignant 45 MSH2 p.G429X high + – ND 4
Adrenal cortical carcinoma 34 MSH2 c.IVS10+1G>A low + – ND 18
Thyroid carcinoma, anaplastic 39 MSH2 p.Q824X low + – ND 18
Thyroid carcinoma, undifferentiated 44 MSH2 c.1704_1705 del AG low + – – C
Pancreatic medullary carcinoma 63 MSH2 c.C1147T p.R383X  high + – – 47
Prostate adenocarcinoma 61 MSH2 c.del exon 5 high + – – 48
Liposarcoma 40 MSH2 c.del AT codon 677 ND + – ND 49
Hepatic cholangiocarcinoma, mucinous 41 MSH2 c.T2026C high + – – 50
Uterine carcinosarcoma 46 MLH1 c.G1896C p.E632D ND – + ND 51
Renal cell carcinoma, clear cellA 51 MLH1 c.C1528T high – ND ND 1
Breast carcinomaA, ductal 34 MLH1 c.C1528T high – ND ND 1
Breast carcinoma, male ductal 71 MLH1 4 bp dup in codon 755-756 high NDB ND ND 52
Breast carcinoma, male 46 MLH1 c.2215-2218 dup AAAC high NDB ND ND 2
ND – not determined, IHC – results from immunohistochemical staining of the tumour for the protein coded by that gene, MSI – classification of the tumour 
microsatellite instability test results
Ain this South-African family 5 breast cancer patients and a relative with renal cell cancer all carried the same mutation and showed microsatellite instability 
and loss of MLH1 protein in their tumours
Bin this tumour loss of heterozygosity for MLH1 was detected
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have a significantly increased risk of developing in their
patients. Cumulative cancer risks for Lynch syndrome
were usually based on retrospective cohort analysis of
families meeting the Amsterdam criteria, often including
families without proven mutations and untested first-
degree relatives. More recently studies have focused
on proven mutation carriers only. The risk figures listed
in Table 1 are based on the latter type of studies 
[8-17]. Interestingly, the risk for gastric, ovarian,
ureter/renal pyelum and brain tumours appears to be
higher for carriers of MSH2 mutations than for carriers
of MLH1 mutations. In addition to the statistical
T Ta ab bl le e   3 3. . Tumours observed in patients with bi-allelic MMR gene germline mutations
T Tu um mo ou ur r   t ty yp pe e M ML LH H1 1 M MS SH H2 2 M MS SH H6 6 P PM MS S2 2
m me ea an n   a ag ge e   ( (r ra an ng ge e) ), ,   N N m me ea an n   a ag ge e   ( (r ra an ng ge e) ), ,   N N m me ea an n   a ag ge e   ( (r ra an ng ge e) ), ,   N N m me ea an n   a ag ge e   ( (r ra an ng ge e) ), ,   N N
Acute leukaemia 2, 1/14
Acute myeloid leukaemia 6, 1/14 7, 1/15
Atypical chronic myeloid leukaemia 1, 1/14
B-acute lymphatic leukaemia 10 (10), 1/43
T-acute lymphatic leukaemia/ 
T cell leukaemia 2, 1/7 2 (2), 1/43
Lymphoblastic lymphoma 5, 1/15 9 (6-15), 3/43
NHL/T-cell lymphoma 3, 1/14 1.7 (1-2), 3/7 10, 1/15 11 (3-17), 4/43
Small bowel carcinoma, not specified 15.5 (15-16), 2/43
Adenocarcinoma duodenum 11, 1/14
Breast cancer 35, 1/14
Colorectal cancer 22 (9-35), 3/14 11.5 (11-12), 2/7 16.6 (8-31), 5/15 15.9 (11-24), 10/43
Endometrial cancer 24, 1/15 23.5 (23-24), 2/43
Brain tumour, not specified 24 (24), 1/43
Glioma 4, 1/14 15 (15), 1/43
Astrocytoma/glioblastoma (multiforme) 4, 1/14 3, 1/7 8 (7-9), 3/15 7.1 (2-17), 8/43
Glioblastoma of the spinal cord 2, 1/15
Oligodendroglioma 10, 1/15 16.5 (14-19), 2/43
Infantile myofibromatosis 1 (1), 1/43
Medulloblastoma 7, 1/14 7, 1/15
Neuroblastoma 13 (13), 1/43
Primitive neuroectodermal tumour 
(PNET) of brain or ovary 11 (4-21), 5/43
Sarcoma 65, 1/14
Ureter/renal pelvis carcinoma 15 (15), 1/43
Wilms’ tumour 4, 1/14
T To ot ta al l 1 14 4   ( (1 11 1   p pa at ti ie en nt ts s) ) 7 7   ( (7 7   p pa at ti ie en nt ts s) ) 1 15 5   ( (1 10 0   p pa at ti ie en nt ts s) ) 4 43 3   ( (2 28 8   p pa at ti ie en nt ts s) )
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For each MMR gene and each of the tumours, the mean age at diagnosis is given in years. If more than one tumour was reported for each type then the
range of ages at diagnosis is shown between brackets. The number of each of the tumour types observed for a particular MMR gene is shown as number/total
of tumours reported for that gene in bi-allelic mutation carriers. Multiple primary tumours were reported frequently and the total number of reported tumours
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approach, the tumour spectrum can be broadened
through analysis of tumours occurring in MMR gene
mutation carriers. Again, patients with atypical Lynch
syndrome tumours as listed in Table 2 more often have
been reported to carry an MSH2 than an MLH1
mutation. Also a wider range of tumours is observed for
MSH2 than for MLH1 in these patients. At this point we
can only speculate on the reason for these differences.
MLH1 and MSH2 each create a heterodimer with
different partners and have different roles in the detection
and repair of DNA mismatches. For each of these
protein complexes, deficiency might have a different
impact on types and quantity of mismatches left
unrepaired and the effect deficiency has on different
target genes. The absence of MSH6 and  PMS2
mutations in Table 2 might simply be caused by the
fact that these mutations have been less frequently
observed in Lynch syndrome in general. Ascertainment
bias, however, cannot be excluded as laboratories did
not test MSH6 and PMS2 in their analyses of Lynch
syndrome suspected patients until fairly recently.
Nevertheless, the absence of MSH6 and PMS2 from
the listed reports might also reflect a true difference in
associated tumour spectrum.
The tumours listed in Table 2 are not known to develop
significantly more frequently in MMR gene mutation
carriers than in the general population. Loss of MMR
function may or may not have contributed significantly to
tumour development in these particular cases. Generally,
in these organs loss of the wild type allele in MMR gene
mutation carriers and/or subsequently the accumulation
of clinically important unrepaired mutations in cancer-
associated target genes are apparently relatively rare.
It is interesting to look at the types of cancer that develop
in patients who have inherited bi-allelic MMR gene
mutations (Tabele 3.). These patients are born with 
a mismatch repair deficiency and can present with
tumours that rarely occur in carriers of single allele MMR
gene mutations who need to lose their WT allele in their
tissues first. Several studies have demonstrated that these
bi-allelic mutations can lead to a phenotypically distinct
recessive syndrome with predominantly childhood onset
brain tumours, leukaemia and lymphoma, bowel tumours
and endometrial carcinoma [20-44]. A striking feature
of these patients is that nearly all of them display some
features, spotty hyperpigmentation of the skin and Lisch
nodules of the irides, usually observed in
neurofibromatosis type I. Some of the reported tumour
types, sarcoma, NHL and early-onset breast cancer
match the types incidentally reported in patients with
single allele MMR gene mutations, which further
supports the notion that these tumour types could be
causally linked to inherited MMR gene mutations.
Whether or not MMR deficiency contributed significantly
to development of the types of cancer occasionally seen
in Lynch syndrome patients remains to be determined.
From a practical point of view, we conclude that unusual
tumours in Lynch syndrome can show loss of
immunohistochemical staining that corresponds to the
MMR germline mutation. Therefore these tumours,
especially of those types that rarely occur in the general
population, could be useful when trying to predict MMR
gene mutations in Lynch syndrome suspected families
for mutation analysis [6, 19] if the typical Lynch
syndrome-associated tumours are unavailable.
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